Regenerating the (para)foveal macula: development of a candidate combination RPE-cone cell therapy for treating geographic atrophy - okulovision is developing a cone progenitor cell (CPC) therapy…
Ended Project Grant Awarded Last action
- Award ID
- R43EY036349
- Recipient
-
Okulovision, Inc. UEI EYWDSUVA7HQ9
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $0
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date
- Place of performance
- Pasadena, CA 91107, USA
Award details come from USAspending.gov.
Description
Regenerating the (para)foveal macula: development of a candidate combination RPE-cone cell therapy for treating geographic atrophy - okulovision is developing a cone progenitor cell (CPC) therapy for treating loss of central vision, particularly in patients with age-related macular degeneration. Cones are essential for central, daytime, high acuity, and color vision, and are concentrated in the very center of the macula in a region called the fovea. This project focuses on building a combination cell graft that can be used to regenerate the parafoveal macula, combining CPC with retinal pigment epithelial (RPE) cells that support cones, on a membrane support that orients RPE properly and facilitates surgical handling.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$295,924 | |
| Original award | $295,924 |
Quick answers
Who received award R43EY036349?
R43EY036349 was awarded to Okulovision, Inc. by National Eye Institute (National Institutes of Health) on September 29, 2024.
How much is award R43EY036349 worth?
$0 has been obligated on R43EY036349.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award